. 2016 Apr 22;17:43. doi: 10.1186/s10194-016-0633-x

Table 6.

Cost-effectiveness sensitivity analysis (4 late responders excluded)

Scenario
Treatment group	Mean cost, €	Mean QALY	ICER^a
Response maintained
nVNS + SoC	7380.93	0.566	nVNS dominant over SoC^b
SoC alone	7540.28	0.536	nVNS dominant over SoC^b
Constant rate of response loss
nVNS + SoC	7392.09	0.550	nVNS dominant over SoC^b
SoC alone	7440.13	0.539	nVNS dominant over SoC^b
Diminishing rate of response loss
nVNS + SoC	7279.89	0.560	nVNS dominant over SoC^b
SoC alone	7385.29	0.537	nVNS dominant over SoC^b

Abbreviations: ICER incremental cost-effectiveness ratio, nVNS non-invasive vagus nerve stimulation, QALY quality-adjusted life-year, SoC standard of care

^aThe expense of gaining an additional QALY with adjunctive nVNS therapy (vs SoC alone)

^bIndicates that adjunctive nVNS therapy was more effective and cost saving than SoC alone